Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.

Mnyani CN, McIntyre JA, Myer L.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):260-4. doi: 10.1097/QAI.0b013e318256b651.

PMID:
22487589
2.

Comparison of point-of-care versus laboratory-based CD4 cell enumeration in HIV-positive pregnant women.

Myer L, Daskilewicz K, McIntyre J, Bekker LG.

J Int AIDS Soc. 2013 Sep 16;16:18649. doi: 10.7448/IAS.16.1.18649.

3.

Ensuring HIV-infected pregnant women start antiretroviral treatment: an operational cohort study from Lilongwe, Malawi.

Weigel R, Hosseinipour MC, Feldacker C, Gareta D, Tweya H, Chiwoko J, Gumulira J, Kalulu M, Mofolo I, Kamanga E, Mwale G, Kadzakumanja A, Jere E, Phiri S.

Trop Med Int Health. 2012 Jun;17(6):751-9. doi: 10.1111/j.1365-3156.2012.02980.x.

4.

Pilot programme for the rapid initiation of antiretroviral therapy in pregnancy in Cape Town, South Africa.

Myer L, Zulliger R, Black S, Pienaar D, Bekker LG.

AIDS Care. 2012;24(8):986-92. doi: 10.1080/09540121.2012.668173.

PMID:
22519561
5.

Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.

Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L.

Trop Med Int Health. 2010 Jul;15(7):825-32. doi: 10.1111/j.1365-3156.2010.02538.x.

6.

Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.

Myer L, Kamkuemah M, Kaplan R, Bekker LG.

Trop Med Int Health. 2013 Nov;18(11):1400-5. doi: 10.1111/tmi.12194.

7.

Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana.

Chen JY, Ogwu AC, Svab P, Lockman S, Moffat HJ, Gaolathe T, Moilwa S, Størdal K, Dryden-Peterson S, Moffat C, Makhema J, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):102-6. doi: 10.1097/QAI.0b013e3181c080bf.

PMID:
19864957
8.

CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.

Carter RJ, Dugan K, El-Sadr WM, Myer L, Otieno J, Pungpapong N, Toro PL, Abrams EJ; MTCT Plus Initiative..

J Acquir Immune Defic Syndr. 2010 Nov;55(3):404-10. doi: 10.1097/QAI.0b013e3181e73f4b.

PMID:
20595905
9.

Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy.

Gupta A, Gupte N, Bhosale R, Kakrani A, Kulkarni V, Nayak U, Thakar M, Sastry J, Bollinger RC; Byramji Jeejeebhoy Medical College-Johns Hopkins University Study Group..

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):338-42.

PMID:
17846559
10.

Impact on ART initiation of point-of-care CD4 testing at HIV diagnosis among HIV-positive youth in Khayelitsha, South Africa.

Patten GE, Wilkinson L, Conradie K, Isaakidis P, Harries AD, Edginton ME, De Azevedo V, van Cutsem G.

J Int AIDS Soc. 2013 Jul 4;16:18518. doi: 10.7448/IAS.16.1.18518.

11.

Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4.

Diaw PA, Daneau G, Coly AA, Ndiaye BP, Wade D, Camara M, Mboup S, Kestens L, Dieye TN.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e103-11. doi: 10.1097/QAI.0b013e318235b378.

PMID:
21909029
12.

Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.

Duran AS, Losso MH, Salomón H, Harris DR, Pampuro S, Soto-Ramirez LE, Duarte G, de Souza RS, Read JS; NISDI Perinatal Study Group..

AIDS. 2007 Jan 11;21(2):199-205.

PMID:
17197811
13.

Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries.

Zolfo M, De Weggheleire A, Schouten E, Lynen L.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):287-9. doi: 10.1097/QAI.0b013e3181eef3da.

PMID:
20714271
14.

Safety, feasibility and efficacy of a rapid ART initiation in pregnancy pilot programme in Cape Town, South Africa.

Black S, Zulliger R, Myer L, Marcus R, Jeneker S, Taliep R, Pienaar D, Wood R, Bekker LG.

S Afr Med J. 2013 Jun 27;103(8):557-62. doi: 10.7196/samj.6565.

PMID:
23885739
15.

Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.

Ciaranello AL, Myer L, Kelly K, Christensen S, Daskilewicz K, Doherty K, Bekker LG, Hou T, Wood R, Francke JA, Wools-Kaloustian K, Freedberg KA, Walensky RP.

PLoS One. 2015 Mar 10;10(3):e0117751. doi: 10.1371/journal.pone.0117751.

16.

Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe.

Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K, Mangwiro A, Bhattacharya G, Lehe J, Peter T.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):1-7. doi: 10.1097/QAI.0b013e3181e93071.

PMID:
20622679
17.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

18.

Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?

Galli L, Puliti D, Chiappini E, Gabiano C, Ferraris G, Mignone F, Viganò A, Giaquinto C, Genovese O, Anzidei G, Badolato R, Buffolano W, Maccabruni A, Salvini F, Cellini M, Ruggeri M, Manzionna M, Bernardi S, Tovo P, de Martino M; Italian Register for HIV Infection in Children..

Clin Infect Dis. 2009 May 1;48(9):1310-7. doi: 10.1086/597774.

PMID:
19309307
19.

Performance evaluation of the Alere PIMA CD4 test for monitoring HIV-infected individuals in resource-constrained settings.

Sukapirom K, Onlamoon N, Thepthai C, Polsrila K, Tassaneetrithep B, Pattanapanyasat K.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):141-7. doi: 10.1097/QAI.0b013e31822866a2.

PMID:
21709568
20.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.

N Engl J Med. 1994 Nov 3;331(18):1173-80.

Supplemental Content

Support Center